Overview

Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Investigation of the outcome of an adjuvant treatment with catumaxomab as compared to surgery alone in patients after curative resection of a gastric adenocarcinoma in order to gain more detailed information primary on safety, tolerability and feasibility and secondary on relevant efficacy parameters.
Phase:
Phase 2
Details
Lead Sponsor:
Neovii Biotech
Treatments:
Antibodies, Bispecific
Catumaxomab